Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7×19-THEMIS CAR-T cells
- Development stage
- Phase 2
- Lead developer
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
7×19-THEMIS CAR-T cells are an investigational, autologous chimeric antigen receptor (CAR) T-cell therapy being developed by the Second Affiliated Hospital of Zhejiang University School of Medicine. This therapy is specifically designed for the treatment of relapsed or refractory large B-cell lymphoma (LBCL). The "7×19" designation refers to the co-expression of Interleukin-7 (IL-7) and the chemokine CCL19, a strategy intended to enhance the survival, expansion, and infiltration of CAR-T cells into tumor tissues by mimicking the microenvironment of secondary lymphoid organs. The "THEMIS" component likely refers to a specific signaling modification or platform used to promote a memory-enhanced T-cell phenotype, which is associated with improved clinical persistence and anti-tumor efficacy. The therapy is currently being evaluated in Phase Ib/II clinical trials to assess its safety and efficacy compared to historical controls.
- Other names
- Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy7×19 CAR-T
02
Targets
Beyond the preview
Go deeper on 7×19-THEMIS CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 7×19-THEMIS CAR-T cells.